State of Alaska Department of Revenue Lowers Stock Position in Integra LifeSciences Holdings Corporation (NASDAQ:IART)

State of Alaska Department of Revenue cut its holdings in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 30.5% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 91,264 shares of the life sciences company’s stock after selling 40,127 shares during the period. State of Alaska Department of Revenue owned 0.12% of Integra LifeSciences worth $2,006,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Quadrant Capital Group LLC increased its stake in Integra LifeSciences by 5,960.9% in the 4th quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company’s stock worth $32,000 after acquiring an additional 1,371 shares during the last quarter. Sterling Capital Management LLC grew its position in Integra LifeSciences by 821.7% in the 4th quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company’s stock valued at $49,000 after acquiring an additional 1,931 shares during the last quarter. Covestor Ltd grew its position in shares of Integra LifeSciences by 61.8% during the 4th quarter. Covestor Ltd now owns 5,423 shares of the life sciences company’s stock worth $123,000 after buying an additional 2,071 shares in the last quarter. NorthRock Partners LLC bought a new position in shares of Integra LifeSciences during the 4th quarter worth $251,000. Finally, Wealth Enhancement Advisory Services LLC bought a new position in shares of Integra LifeSciences during the 1st quarter worth $251,000. 84.78% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Stock Performance

Shares of Integra LifeSciences stock opened at $11.62 on Tuesday. Integra LifeSciences Holdings Corporation has a one year low of $11.06 and a one year high of $32.66. The company has a market cap of $902.99 million, a price-to-earnings ratio of -30.58, a PEG ratio of 0.65 and a beta of 1.17. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.72 and a current ratio of 1.21. The business’s 50 day moving average price is $13.78 and its 200 day moving average price is $19.66.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Monday, May 5th. The life sciences company reported $0.41 EPS for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.02). Integra LifeSciences had a positive return on equity of 12.12% and a negative net margin of 1.78%. The company had revenue of $382.65 million for the quarter, compared to analysts’ expectations of $381.17 million. During the same quarter in the previous year, the business posted $0.55 EPS. The business’s quarterly revenue was up 3.7% compared to the same quarter last year. On average, research analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Wells Fargo & Company decreased their price objective on Integra LifeSciences from $25.00 to $13.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 6th. Argus upgraded Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Monday, March 31st. JPMorgan Chase & Co. dropped their target price on Integra LifeSciences from $24.00 to $12.00 and set an “underweight” rating on the stock in a report on Tuesday, May 6th. Truist Financial dropped their target price on Integra LifeSciences from $26.00 to $19.00 and set a “hold” rating on the stock in a report on Friday, April 11th. Finally, JMP Securities dropped their price objective on Integra LifeSciences from $35.00 to $25.00 and set a “market outperform” rating on the stock in a report on Friday, May 9th. Four research analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, Integra LifeSciences presently has an average rating of “Hold” and a consensus price target of $18.63.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.